Secondary loss of effectiveness among rheumatoid arthritis patients treated with tumour necrosis factor inhibitors

被引：0
|
作者：
Aaltonen, K. [1 ]
Isomaki, P. [2 ,3 ]
Joensuu, J. [1 ]
Sokka, T. [4 ,5 ]
Peltomaa, R. [6 ]
Piril, L. [7 ]
Varjolahti-Lehtinen, T. [8 ]
Uutela, T. [9 ]
Malmi, T. [10 ]
Ekman, P. [11 ]
Kononoff, A. [12 ]
Eklund, K. [6 ,13 ]
机构：
[1] Univ Helsinki, Fac Pharm, Helsinki, Finland
[2] Tampere Univ Hosp, Dept Med, Tampere, Finland
[3] Univ Tampere, Fac Med, Tampere, Finland
[4] Jyvaskyla Cent Hosp, Dept Med, Jyvaskyla, Finland
[5] Univ Eastern Finland, Fac Hlth Sci, Kuopio, Finland
[6] Univ Helsinki, Dept Med, Cent Hosp, Helsinki, Finland
[7] Turku Univ Hosp, Dept Med, Turku, Finland
[8] Tampere City Hosp, Dept Med, Tampere, Finland
[9] Lapland Cent Hosp, Dept Med, Rovaniemi, Finland
[10] Seinajoki Cent Hosp, Dept Med, Seinajoki, Finland
[11] Rauma Cent Hosp, Dept Med, Rauma, Finland
[12] Kuopio Univ Hosp, Dept Med, Kuopio, Finland
[13] Univ Helsinki, Fac Med, Helsinki, Finland
来源：
SCANDINAVIAN JOURNAL OF RHEUMATOLOGY | 2017年 / 46卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：419 / 420
页数：2
相关论文
共 50 条
  • [41] Risk of Heart Failure in Rheumatoid Arthritis Patients Treated with Tumor Necrosis Factor-α Inhibitors
    Chen, Hung-Kai
    Shao, Shih-Chieh
    Weng, Meng-Yu
    Lin, Swu-Jane
    Hung, Ming-Jui
    Chan, Yuk-Ying
    Lai, Edward Chia-Cheng
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2021, 110 (06) : 1595 - 1603
  • [42] Survival in Patients with Rheumatoid Arthritis and Early Breast Cancer Treated with Tumor Necrosis Factor Inhibitors
    Suarez-Almazor, Maria
    Ruiz, Juan
    Lei, Xiudong
    Wu, Chi-Fang
    Zhao, Hui
    Rajan, Suja
    Lin, Heather
    Giordano, Sharon
    [J]. ARTHRITIS & RHEUMATOLOGY, 2023, 75 : 3328 - 3329
  • [43] Risk factors for herpes zoster in rheumatoid arthritis patients: the role of tumour necrosis factor-α inhibitors
    Segan, J.
    Staples, M. P.
    March, L.
    Lassere, M.
    Chakravarty, E. F.
    Buchbinder, R.
    [J]. INTERNAL MEDICINE JOURNAL, 2015, 45 (03) : 310 - 318
  • [44] A MODEL TO EVALUATE THE IMMUNOGENICITY COSTS OF TUMOUR NECROSIS FACTOR-ALPHA INHIBITORS IN PATIENTS WITH RHEUMATOID ARTHRITIS
    Heeg, B.
    Majer, I
    Stephens, J. M.
    Tarallo, M.
    [J]. VALUE IN HEALTH, 2013, 16 (07) : A563 - A563
  • [45] Survival in patients with rheumatoid arthritis and early breast cancer treated with tumor necrosis factor inhibitors
    Ruiz, Juan I.
    Lei, Xiudong
    Wu, Chi-Fang
    Giordano, Sharon H.
    Zhao, Hui
    Rajan, Suja S.
    Lin, Heather
    Suarez-Almazor, Maria E.
    [J]. BREAST CANCER, 2024,
  • [46] Drugs that block tumour necrosis factor: Experience in patients with rheumatoid arthritis
    Moreland, LW
    [J]. PHARMACOECONOMICS, 2004, 22 (02) : 39 - 53
  • [47] Drugs that block tumour necrosis factor: Experience in patients with rheumatoid arthritis
    Larry W. Moreland
    [J]. PharmacoEconomics, 2004, 22 : 39 - 53
  • [48] Tumour necrosis factor a −308 promoter polymorphism in patients with rheumatoid arthritis
    Zahra Rezaieyazdi
    Jalil Tavakol Afshari
    Mahnaz Sandooghi
    Farnaz Mohajer
    [J]. Rheumatology International, 2007, 28 : 189 - 191
  • [49] MORTALITY IN PATIENTS WITH RHEUMATOID ARTHRITIS AND INTERSTITIAL LUNG DISEASE TREATED WITH TUMOUR NECROSIS FACTOR INHIBITOR OR RITUXIMAB
    Druce, Katie L.
    Iqbal, Kundan
    Watson, Kath
    Symmons, Deborah P. M.
    Hyrich, Kimme L.
    Kelly, Clive
    [J]. RHEUMATOLOGY, 2017, 56 : 127 - 128
  • [50] The effectiveness of leflunomide as a co-therapy of tumour necrosis factor inhibitors in rheumatoid arthritis: a population-based study
    Finckh, A.
    Dehler, S.
    Gabay, C.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2009, 68 (01) : 33 - 39
12345